

Subscribe to
Bioshares
\$550/
48 issues

More details can be found
on the back page

Companies covered: AVR, IMM, IXC

	Bioshares Portfolio
Year 1 (May '01 - May '02)	21.2%
Year 2 (May '02 - May '03)	-9.4%
Year 3 (May '03 - May '04)	70.6%
Year 4 (May '04 - May '05)	-16.3%
Year 5 (May '05 - May '06)	77.8%
Year 6 (May '06 - May '07)	17.4%
Year 7 (May '07 - May '08)	-35.8%
Year 8 (May '08 - May '09)	-7.4%
Year 9 (May '09 - May '10)	50.2%
Year 10 (May '10 - May '11)	45.4%
Year 11 (May '11 - May '12)	-18.0%
Year 12 (May '12 - May '13)	3.1%
Year 13 (May '13 - May '14)	26.6%
Year 14 (May '14 - May '15)	23.0%
Year 15 (May '15 - May '16)	33.0%
Year 16 (May '16 - May '17)	16.8%
Year 17 (May '17 - May '18)	-7.1%
Year 18 (May '18 - May '19)	-2.3%
Year 19 (May '19 - May '20)	39.5%
Year 20 (May '20 - Current)	84.4%
Cumulative Gain	1908%
Av. Annual gain (20 yrs)	20.6%

Bioshares is published by Blake Industry & Market Analysis Pty Ltd.

Blake Industry & Market Analysis Pty Ltd
ACN 085 334 292
PO Box 193
Richmond Vic 3121
AFS Licence No. 258032
Enquiries for *Bioshares*
Ph: (03) 9326 5382
Fax: DISCONTINUED
Email: info[at]bioshares.com.au

David Blake - Editor/Analyst
Ph: (03) 9326 5382
Email: david[at]bioshares.com.au

Mark Pachacz - Editor/Analyst
Ph: 0403 850 425
Email: mark[at]bioshares.com.au

Individual Subscriptions (48 issues/year)
\$550 (Inc.GST)
Edition Number 885 (29 March 2021)

Copyright 2021 Blake Industry and Market Analysis Pty Ltd. ALL RIGHTS RESERVED.
Secondary electronic transmission, photocopying, reproduction or quotation is strictly prohibited without written consent of the publisher.

Bioshares

29 March 2021
Edition 885

Delivering independent investment research to investors on Australian
biotech, pharma and healthcare companies

Extract from *Bioshares* –

Anteris Demonstrates ADAPT Process Outperforms Medtronic's AOA Process in Animal Study

Anteris Technologies (AVR: \$12.94) has released the results of a competitive study of tissue used in heart valves treated using its proprietary anti-calcification technology (ADAPT) versus an on-market process (AOA, or alpha amino oleic acid), as used to process tissue used in Medtronic's heart valve products.


The study was conducted in 48 rats, over four and eight months, which had been implanted with four different tissue samples, being ADAPT treated tissue, AOA treated porcine tissue, AOA treated bovine tissue and glutaldehydhe treated tissue (a control).

The tissue samples were studied for calcium content. Calcification of tissue used in heart valves has limited the implantation of heart valves into younger patients. Anteris' novel ADAPT technology has shown no calcification more than 10 years after processing and implantation in humans.

The study showed ADAPT treated tissue yielded a mean 26% less calcium than AOA treated bovine tissue ($p=0.007$) and a mean 38% less calcium than AOA treated porcine tissue ($p<0.001$).

The data from this study will serve the company in discussions with both the FDA and potential commercial partners. It complements the positive results that have emerged from the company's 15 patient trial which has been ongoing in Belgium (last discussed in *Bioshares* 871) in which favourable hemodynamic results from the first five patients have been achieved.

Continued over



Bioshares Model Portfolio (29 March 2021)

Company	Code	Price (current)	Price added to portfolio	Recommendation	Cap'n (\$M)	Date added
Clinuvel Pharmaceuticals	CUV	\$27.68	\$20.31	Buy	\$1,368	November 2020
Opthea	OPT	\$1.470	\$0.160	Spec Buy A	\$496	November 2014
Immutep	IMM	\$0.415	\$0.320	Spec Buy A	\$202	March 2019
Cyclopharm	CYC	\$2.540	\$1.35	Spec Buy A	\$201	September 2019
Cogstate	CGS	\$0.935	\$0.24	Spec Buy A	\$159	April 2019
Micro-X	MX1	\$0.350	\$0.38	Spec Buy A	\$126	May 2017
Cynata Therapeutics	CYP	\$0.610	\$0.70	Spec Buy B	\$87	December 2020
Dimerix	DXB	\$0.265	\$0.09	Spec Buy A	\$52	December 2018
Patrys	PAB	\$0.028	\$0.013	Spec Buy B	\$51	July 2020
Adalta	1AD	\$0.170	\$0.07	Spec Buy B	\$42	May 2020
Pharmaxis	PXS	\$0.080	\$0.260	Spec Buy B	\$32	December 2016
Acrux	ACR	\$0.155	\$0.31	Spec Buy A	\$26	July 2017

Portfolio Changes – 29 March, 2021

IN:
No changes

OUT:
No changes

Stocks Removed from Bioshares Portfolio in TTM

Date removed	Stock
October 2020	RNO, SOM, VHT
August 2020	TLX

– Anteris cont'd

Summary

We have re-rated Anteris Technologies from a **Speculative Hold Class B** to **Speculative Buy Class B**. A positive shift in sentiment towards the company has seen its share price increase by almost 250% from last year. A stronger share price could aid the company should it wish to inject fresh equity and thus be less reliant on a \$16.5 million drawn facility it established with Mercer Street Global Opportunity Fund in January 2021.

The company's capitalisation of \$85 million is yet to reflect the upside that exists from the introduction of both a competitive tissue processing technology and novel 3D heart valve device into the world's multi-billion heart valve market.

As more data emerges from the 15 patient Belgium trial, which confirms the favourable hemodynamics of the 3D DurAVR single piece valve obtained to date, then the more stable the stock price is likely to remain, and at higher levels.

A major technical challenge ahead for the company is the development of the techniques needed to implant the 3D DurAVR in a transcatheter valve procedure.

At December 31, 2021, the company held \$4.4 million in cash. In January is secured \$1.1 million via a placement, and \$1.22 million from an R&D tax refund backed facility, as well as access to a \$16.5 million draw-down facility.

Anteris also has 2.37 million, 18 Dec 21, \$8.00 Options trading (AVRO: \$5.50), which were issued as free attached options in conjunction with a rights issue in December 2018. If exercised these could raise an additional \$19 million in funds.

Bioshares recommendation: **Speculative Buy Class B**

Bioshares

How Bioshares Rates Stocks

For the purpose of valuation, Bioshares divides biotech stocks into two categories. The first group are stocks with existing positive cash flows or close to producing positive cash flows. The second group are stocks without near term positive cash flows, history of losses, or at early stages of commercialisation. In this second group, which are essentially speculative propositions, Bioshares grades them according to relative risk within that group, to better reflect the very large spread of risk within those stocks. For both groups, the rating “Take Some Profits” means that investors may re-weight their holding by selling between 25%-75% of a stock.

Group A

Stocks with existing positive cash flows or close to producing positive cash flows.

- Buy** CMP is 20% < Fair Value
- Accumulate** CMP is 10% < Fair Value
- Hold** Value = CMP
- Lighten** CMP is 10% > Fair Value
- Sell** CMP is 20% > Fair Value
(CMP–Current Market Price)

Group B

Stocks without near term positive cash flows, history of losses, or at early stages of commercialisation.

Speculative Buy – Class A

These stocks will have more than one technology, product or investment in development, with perhaps those same technologies offering multiple opportunities. These features, coupled to the presence of alliances, partnerships and scientific advisory boards, indicate the stock is relative less risky than other biotech stocks.

Speculative Buy – Class B

These stocks may have more than one product or opportunity, and may even be close to market. However, they are likely to be lacking in several key areas. For example, their cash position is weak, or management or board may need strengthening.

Speculative Buy – Class C

These stocks generally have one product in development and lack many external validation features.

Speculative Hold – Class A or B or C

Sell

Corporate Subscribers: Cogstate, LBT Innovations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta, Actinogen Medical, Patrys, Cyclopharm, Antisense Therapeutics, Imugene, Exopharm, Immutep, Neuroscientific Biopharmaceuticals, Invex Therapeutics, Anteris Technologies, Chimeric Therapeutics

Disclaimer:

Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst DB: ACR,ADR,COH,CSL,CYC,HXL, MX1,OPT,SOM,TLX. Analyst MP: ACR,CGS, CYC, IMM, OPT,CUV,MX1,PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not disclosed.

Subscription Rates (inc. GST)

48 issues per year (electronic distribution): **\$550**

For multiple email distributions within \$900 2-3 email addresses
 the same business cost centre, our \$1200 4-5 email addresses
 pricing structure is as follows: \$1500 6-10 email addresses

To subscribe, post/email this subscription form to: **Bioshares**
PO Box 193 Richmond VIC 3121
info@bioshares.com.au

I enclose a cheque for \$ _____ made payable to **Blake Industry & Market Analysis Pty Ltd**, or

Please charge my credit card \$ _____ MasterCard Visa

Card Number

Signature _____ Expiry date _____

Subscriber details

Name _____

Organisation _____

Ph () _____

Emails _____

The information provided in Bioshares, including general investment advice, is provided only for receipt and use in Australia and New Zealand, for subscribers to Bioshares, who are Australian or New Zealand citizens or commercial entities.